Alcohol Dysregulates Corticotropin-Releasing-Hormone (CRH) Promoter Activity by Interfering with the Negative Glucocorticoid Response Element (nGRE) by Przybycien-Szymanska, Magdalena M. et al.
Alcohol Dysregulates Corticotropin-Releasing-Hormone
(CRH) Promoter Activity by Interfering with the Negative
Glucocorticoid Response Element (nGRE)
Magdalena M. Przybycien-Szymanska, Natasha N. Mott, Toni R. Pak*
Department of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, United States of America
Abstract
EtOH exposure in male rats increases corticotropin-releasing hormone (CRH) mRNA in the paraventricular nucleus of the
hypothalamus (PVN), a brain region responsible for coordinating stress and anxiety responses. In this study we identified the
molecular mechanisms involved in mediating these effects by examining the direct effects of EtOH on CRH promoter
activity in a neuronal cell line derived from the PVN (IVB). In addition, we investigated the potential interactions of EtOH and
glucocorticoids on the CRH promoter by concomitantly treating cells with EtOH and the glucocorticoid receptor (GR)
antagonist RU486, and by sequentially deleting GR binding sites within glucocorticoid response element (GRE) on the CRH
promoter. Cells were transiently transfected with a firefly luciferase reporter construct containing 2.5 kb of the rat wild type
(WT) or mutated CRH promoter. Our results showed that EtOH treatment induced a biphasic response in CRH promoter
activity. EtOH exposure for 0.5 h significantly decreased promoter activity compared to vehicle treated controls, whereas
promoter activity was significantly increased after 2.0 h of EtOH exposure. Treatment with RU486, or deletion of the GR
binding sites 1 and 2 within the GRE, abolished the EtOH-induced increase in the promoter activity, however did not affect
EtOH-induced decrease in CRH promoter activity at an earlier time point. Overall, our data suggest that alcohol exposure
directly regulates CRH promoter activity by interfering with the normal feedback mechanisms of glucocorticoids mediated
by GR signaling at the GRE site of the CRH promoter.
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Introduction
Alcohol is a potent activator of the hypothalamo-pituitary adrenal
(HPA) axis, as manifested by immediate increases in circulating
glucocorticoids following exposure [1,2,3,4,5]. Although the effects of
alcohol on HPA function have been well described, our understand-
ing of the molecular mechanisms regulating alcohol effects on the
HPA axis remain poorly defined. Corticotrophin-releasing hormone
(CRH)-expressing neurons located in the paraventricular nucleus of
the hypothalamus (PVN) play a pivotal role in orchestrating the
central stress response and proper functioning of these neurons is
critical for maintaining a homeostatic state following a stressful event.
The HPA axis is a three-tiered biological system that begins at the
highestlevel with CRH release from the PVN potentiating the release
of adrenocorticotrophin hormone (ACTH) from the anterior
pituitary gland. ACTH acts, in turn, on the adrenal glands to
increase the production and release of glucocorticoid hormones [6].
Glucocorticoids (CORT) can then exert negative feedback on both
the hypothalamus and pituitary gland to decrease CRH and ACTH
release [6,7,8].
We previously demonstrated that binge-pattern alcohol exposure
during pubertal development increased both circulating plasma
CORT levels and CRH mRNA expression in the PVN [4],
suggesting that alcohol exposure disrupted normal glucocorticoid
negative feedback pathways. Glucocorticoid negative feedback is
mediated, in part, by the activation of glucocorticoid receptors
(GR), which belong to the superfamily of nuclear steroid
receptors. Upon activation by glucocorticoids, GRs undergo
dimerization, translocate to the nucleus, and modulate gene
transcription [9,10,11,12]. In the PVN, GRs are known to
decrease CRH gene transcription through signaling at the
negative glucocorticoid response element (nGRE), located
between 2249 and 2278 nucleotides upstream from the
transcription start site of the CRH promoter. Overall, glucocor-
ticoids acting through GRs decrease CRH promoter activity
thereby, decreasing transcriptional activity of the promoter and
decreasing CRH gene expression.
Based on our previous observations that binge-pattern EtOH
exposure in pubertal rats increased CRH gene expression in the
PVN [4], we tested the hypothesis that ethanol (EtOH) increases
CRH gene expression by directly interfering with glucocorticoid
negative feedback at the level of the CRH promoter. The overall
goals of this study were to determine if 1) EtOH directly modulates
CRH promoter activity and 2), to identify a putative site of action
for EtOH on the CRH promoter. Overall, our results showed that
EtOH differentially modulated CRH promoter activity in a time-
dependent manner. Further, these effects were mediated, in part,
through the nGRE site on the CRH promoter. Taken together, our
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GR:CRH signaling which, if occurs during adolescence, may be
detrimental for proper maturation of the HPA axis.
Materials and Methods
Cell Culture
The IVB cell line, derived from the rat hypothalamic PVN, was
used for all transient transfections (generously provided by Dr.
John Kaskow, University of Cincinnati) and was verified to be free
of mycoplasma contamination (data not shown, MycoSensor
QPCR, Stratagene/Agilent Technologies). Cells were maintained
in DMEM containing 4.5% glucose and L-glutamine (HyClone
Laboratories, Logan, UT) supplemented with 10% fetal bovine
serum. Cells were grown to 90% confluence and all transient
transfections were performed within 10 passages.
Reporter gene constructs and expression vectors
The full-length rat CRH promoter was generously provided and
validated by Dr. Audrey F. Seasholtz (University of Michigan, Ann
Arbor, MI) and then modified as follows. The full- length
promoter fragment (22125/+94) was excised from the pUC18
vector by restriction enzyme digestion for EcoR1 (59) and
HINDIII (39) and subsequently subcloned into the promoterless
luciferase vector (pGL3 basic, Promega Corp., Madison, WI). The
pRL-tk-luciferase reporter vector (Promega Corp., Madison, WI)
was used as an internal control for calculating plasmid transfection
efficiency.
Transient Transfections and Dual Luciferase Assay
Cells were plated at the density of 20, 000 cells/well in opaque
96-well plate for 24 hours prior to transfection to achieve a final
confluency of 70–90%. Transient transfections were performed in
replicates of 6 wells/plate for each construct/treatment and each
assay was repeated minimum of 6 times (N=6). Transfections
were achieved using a lipid-mediated transfection reagent,
Fugene6 (Roche Molecular Biomedical, Indianapolis, IN) accord-
ing to manufacturer’s instructions. Twenty-four hours following
transfection, cells were treated (see below) and then processed for
luciferase assays (Dual Luciferase Reporter (DLR) kit (Promega
Inc., Madison, WI). Briefly, cells were lysed in 20 ml of lysis buffer,
incubated on a shaker for 20 min at room temperature, and then
loaded into a multiple well plate reader (Synergy HT, Biotech).
The plate reader is equipped with dual injectors and automatically
dispenses 100 ml firefly luciferase substrate (LARII) followed by
‘‘stop-and glo’’ substrate for renilla luciferase. Results were
analyzed using Gen5 software (Biotech Inc., Winooski, VT).
EtOH and Forskolin Treatments
Twenty-four hours after transfection with the CRH promoter,
cells were incubated with varying concentrations of EtOH (12.5,
25.0, 50.0 or 100 mM) diluted in 10% FBS media (vehicle) for
2.0 h (dose response experiments), or they were treated with
12.5 mM EtOH for either 0.5, 1.0, 2.0, 4.0 h (time course studies).
Cells transfected with the mutated CRH promoter that lacked
specific GR regulatory regions were treated with 12.5 mM EtOH
or vehicle for 0.5, 1.0, 2.0 or 4.0, or 8 h or, in control experiments,
they were treated with 25 mM Forskolin for 6.0 h.
Kinase Inhibitors
The following kinase inhibitors were purchased from Sigma
Aldrich (St. Louis, MO)and used at a concentration of 10 mM each:
LY 294,002 (PI3K inhibitor), SB 202190 (p38 MAPK inhibitor),
and H89 (PKA inhibitor). Twenty-four hours after transfection (as
described above), cells were exposed to concomitant treatment with
kinase inhibitors and 12.5 mM EtOH, or kinase inhibitor alone, for
0.5, 1.0, or 2.0 h.
Site-Directed Mutagenesis
Scanning mutagenesis deletions were performed on the CRH
promoter using the QuickChange II XL kit according to manufac-
turer’s instructions (Stratagene, LaJolla, CA). Briefly, forward and
reverse primer sequences were designed targeting the appropriate
identified regions of the promoters (GR binding site 1, (59-
CTTGGATAATCTCATTCAAGAACAATGGACAAGTCATA-
AGAGC-39;5 9-GAACCTATTAGAGTAAGTTCTTGTTACCT-
GTTCAGTATTCTTCG-39), GR binding site 2 (59-CTCATT-
CAAGAATTTTTGTCAACAAGTCATAAGAAGCCCTTCCA-
39;5 9-GAGTAAGTTCTTAAAAACAGTTGTTCAGTATTCT-
TCGGGAAGGR-39), and GR binding site 1 and 2 double deletion
(59-GGATAATCTCATTCAAGAACAAAGTCATAAGAAGCC-
CTTCCA-39;5 9TGGAAGGGCTTCTTATGACTTTGTTCTT-
GAATGAGATTATCC-39. Sequences contained deletions of 7, 4,
or 6 bp, respectively, sequentially from 59 to 39 in these regions
(Fig. 1). A standard PCR reaction was performed on a thermal cycler
using mutated CRH-luciferase construct as a template. Following the
reaction, the parent plasmid was digested using the DpnI restriction
enzyme and the daughter plasmid, containing the desired mutation
Figure 1. Schematic representation of mutant CRH promoter constructs. Diagrams depicting specific nucleotide sequences deleted within
the nGRE site of the CRH promoter located between 2249 and 2278 bp upstream from the transcription initiation site (arrow).
doi:10.1371/journal.pone.0026647.g001
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The mutation was confirmed by DNA sequencing using the in-house
core sequencing facility (Loyola University Chicago, Stritch School of
Medicine).
qRT-PCR
GRgene expression levelswere measuredinIVBcells afterEtOH
treatment. Cells were plated at the density of 200,000 cells/well in
clear6-well plate untiltheyachieved final confluenceof 90%.At that
time (approximately 72.0 h later) cells were treated with 100 mM
EtOH or vehicle for 0.5 or 2.0 h. After appropriate treatment times,
cells were washed 2 times with cold PBS and 1 ml of Trizol was
addedtoeachwell.TotalRNAisolationwasperformedonsonicated
samples using Trizol reagent (Invitrogen Inc., Carlsbad, CA)
according to the manufacturer’s directions. Following RNA
isolation, 0.5 mg total RNA was reverse transcribed using the First
Strand Synthesis SuperMix for qRT-PCR (Invitrogen Inc.,
Carlsbad, CA). Roche FastStart SYBR Green Master Mix was
added to GR specific upper and lower primer (0.25 mMf i n a l
concentration; 5-AAACCTCAATAGGTCGACCAGCGT; 5-AG-
GTGCTTTGGTCTGTGGGATACA). Then, 2 mLc D N At e m -
plates were added to duplicate reactions performed in 96 well plates.
Quantification of the target gene expression was achieved by
extrapolating from standard curve of known concentrations of
the hypoxanthine guanine phosphoribosyl transferase 1 (HPRT)
housekeeping gene ran simultaneously in the same plate. All samples
werenormalized tothe HPRThousekeeping gene,as itisnot altered
by EtOH treatment [4].
Western Blot Analysis
Cells at a density of 10
5 cells/dish were treated with vehicle
(10% FBS media) or 100 mM EtOH for 0.5 or 2.0 h. Total
protein was isolated using Tissue Protein Extraction Reagent
(Thermo Scientific, Waltham, MA) supplemented with proteinase
inhibitor cocktail (Roche catalogue #04693159001; 7x stock
solution), according to manufacturer’s instructions. 60 mgo f
protein was loaded onto 10% SDS-PAGE gel and then transferred
onto a PVDF membrane (Millipore, Billerica, MA). The
membrane was blocked with 5% milk for 0.5 h and then
incubated with GR N499 primary antibody (3 mg/ml, generously
provided by Dr. Keith Yammamoto, University of California, San
Francisco, 1:2500 concentration in 2.0% milk) overnight at 4uC.
Following incubation, the membrane was washed three rimes
10 min in 10 ml TBST (Tris Base Solution containing 0.1%
Tween 20), incubated in secondary antibody (HRP conjugated
goat anti rabbit IgG, Santa Cruz Biotechnology, 1:6000
concentration in 2% milk) for 1.5 h, and washed three times
10 min in TBST. The blot was then developed using Super-Signal
West Pico Chemiluminescent Substrate (Thermo Scientific,
Waltham, MA) and Kodak Biomax Light Film according to
manufacturer’s directions.
In order to control loading efficiency, blots were stripped, re-
blocked with 5% milk and then incubated in primary goat beta
actin antibody at 1:400 dilution in 2% milk for 2.0 h, washed three
times 10 min in TBST, incubated in HRP conjugated donkey anti
goat IgG (Sabta Cruz Biotechnology, 1:5000 dilution in 2% milk)
for 1.5 h, and washed three times 10 min in TBST. Following
antibody applications and washes, the membrane was developed
according to the procedure described above.
Chromatin Immunoprecipitation Assay (ChIP)
PVN-derived IVB cells were incubated at a density of 10
6 cells/
15 cm plate and were treated with vehicle, 100 mM Dexametho-
sone (DEX, positive control) or 100 mM EtOH for 2 h. ChIP
assay was performed using EZ-Magna ChIP G Chromatin
Immunoprecipitation kit (Millipore, Billerica, MA) according to
manufacturer’s instructions. Briefly, following formaldehyde cross-
linking cell lysate was sonicated on wet ice 5X/5 sec using Fisher
Scientific Sonic Dimembrator Model 100 and then centrifuged to
pellet the debris. The supernatant was collected into 50 ml aliquots
and stored in 280uC until further processing. Immunoprecipita-
tion of crosslinked GR-DNA complex was performed by overnight
incubation with 12 mg of GR N499 antibody (generously provided
by Dr. Keith Yamamoto, University of California, San Francisco)
and diluted in ChIP Dilution Buffer supplied in the kit. GR/DNA
complexes were reverse crosslinked and the DNA was purified
using spin columns provided in the kit. To perform standard end
point PCR, CRH promoter specific upper and lower primers
(0.25 mM final concentration; 5-TTCTCTCTCCCACTCTGCC-
TCTTT; 5-TTGGTGACGTCAACGAGCCCTAAA) were add-
ed to 5 ml DNA. The PCR product was then analyzed using
standard agarose gel electrophoresis. Control GAPDH primers
(providedinkit)wereusedtoanalyzetheloadingefficiency(input)in
the ChIP reaction.
In Vitro Toxicology Assay (MTT based)
Cell viability was measured using in vitro3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) MTT based Toxicology assay
(Sigma-Aldrich) according to manufacturer’s instructions. Briefly,
following EtOH treatments cells were washed once with sterile PBS
and media was replaced with 250 ml of a 0.25 mg/ml solution of
MTT in regular growth media without FBS and phenol red. Cells
were incubated in the MTT solutions for 1.5 h at 37uC; then MTT
solution was removed, MTT solubilization solution (200 mlo f
0.04 M HCl in absolute isopropanol) was added to eachsample and
transferred to 96-well plate. Absorbance was read at 570 nm on a
multimode multiplate reader (Biotech Inc., Wonooski, VT).
Statistical Analysis
One-way ANOVA was used to test for differences between
specific treatment groups followed by Tukey’s post-hoc test if one-
way significance was indicated. A Student’s t-test was used in order
to compare differences between vehicle and EtOH treatment
within each deletion mutation. All tests were performed using
SigmaStat Statistical Analysis Software. A p-value of less than 0.05
was considered to be significant.
Results
EtOH treatment altered CRH promoter activity in a time-
dependent manner
To determine whether EtOH alters CRH promoter activity, we
used an in vitro reporter gene assay and added EtOH directly to the
cell culture media (rat PVN-derived cell line (IVB). Our results
showed that treatment with 100 mMEtOH had a biphasiceffecton
CRHpromoteractivity(F(4,28)=15.331,p,0.001,N=6,Fig.2A).
Notably, EtOH significantly decreased CRHpromoteractivityafter
0.5 h (p=0.002), whereas EtOH significantly increased the
promoter activity after 2.0 h (p=0.043). We then treated the cells
with EtOH in the presence of a glucocorticoid receptor antagonist
(RU486) in order to ascertain whether EtOH interacted with
glucocorticoid negative feedback mechanisms at the level of the
CRH promoter. Treatment with RU486 completely abolished the
EtOH-induced increase in CRH promoter activity observed after
2.0 h of EtOH treatment, suggesting that EtOH might interact with
glucocorticoid receptors to alter CRH promoter activity. Interest-
ingly, treatment with RU486 did not affect the EtOH-induced
EtOH Activation of CRH Promoter Depends on GRE
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treatment (Fig. 2B).
EtOH increased CRH promoter activity at 2.0 h time point
at all doses tested
The results obtained from initial experiments in Figure 2
demonstrated that EtOH alters CRH promoter activity. The dose
used in those experiments (100 mM) was based on previously
published studies that used EtOH treatment in a cell culture model
system however, the physiological relevance of this high dose is
questionable given that the blood alcohol level corresponding to the
legal limit for driving (0.08%) is equivalent to about 25 mM
[13,14,15,16,17,18]. Therefore, we tested CRH promoter activity
in the presence of varying doses of EtOH in order to establish the
minimal effective dose. The highest dose (100 mM) increased CRH
promoter activity to the same degree following 2.0 h of EtOH
treatment as observed in the previous time course experiments
(Figs. 2A and 3). Surprisingly, however, EtOH significantly
increased CRH promoter activity at all of the lower doses we
tested compared to vehicle treated control (F(4,45)=2.665,
p=0.044, N=6, Fig. 3). Also, there was no dose response observed,
suggesting that lowest 12.5 mM dose is sufficient to elicit a maximal
response of CRH promoter activity. Thus, for all subsequent studies
the 12.5 mM dose was used in order to be consistent with doses that
were more physiologically relevant.
Deletion of GR binding sites within nGRE abolished the
alcohol induced increase in CRH promoter activity at
2.0 h
Our initial observations using the GR antagonist RU486
suggested that EtOH might alter CRH promoter activity by
interfering with GR and normal glucocorticoid negative feedback
pathways. We screened the promoter sequence and identified two
GR binding sites located proximal to the transcription start
site. Site-directed mutagenesis was performed to delete each
site individually (CRHDGR1 and CRHDGR2) or concurrently
(CRHDGR1/2). One-way ANOVA indicated that the GR binding
site deletions had a significant effect on basal CRH promoter
Figure 2. Effects of EtOH treatment (A) and RU486 pre-treatment (B) on CRH promoter activity in a neuronal cell line. CRH-luciferase
activity was measured in IVB cell line after treatment with 100 mM EtOH for 0.5, 1.0, 2.0 or 4.0 h or media alone (A) and after 16 h pretreatment with
100 nM RU486 and 100 mM ETOH/100 nM RU486 co-treatment for 0.5, 1.0, 2.0 or 4.0 h (B). Data expressed as % change in luciferase activity of
vehicle treated control. Dissimilar letters indicate statistically significant difference (P,0.05).
doi:10.1371/journal.pone.0026647.g002
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CRHDGR1 and CRHDGR2 significantly increased basal CRH
promoter activity (p,0.001), whereas deletion of both GR binding
sites (CRHDGR1/2) did not affect basal CRH promoter activity
(p=0.551). Deletion of GR binding site 1, 2 or both (CRHDGR1,
CRHDGR2 or CRHDGR1/2) abolished the previously observed
EtOH-induced increase in CRH promoter activity at the 2.0 h time
point (p=0.764. p=0.836 and p=0.457, respectively, Fig. 4), yet
did not affect the EtOH-induced decrease in CRH promoter
activity at seen at 0.5 h (Fig. 4). Interestingly, individual deletion of
GR binding sites 1 or 2 did not abolish the EtOH-induced increase
in CRH promoter activity rather, the time course was delayed such
that the promoteractivityincreasedafter4 hours ofEtOHexposure
as opposed to the previously observed increase at 2.0 h (Figs. 2, 3
and 4). EtOH did not induce CRH promoter activity in the double
deletion mutant (CRHDGR1/2) even after 8 hours of EtOH
exposure (data not shown).
Validation of the mutated CRH promoter constructs was
confirmed by treatment with 25 mM forskolin, which is a potent
activator the CRH promoter. As expected, forskolin treatment
significantly increased CRH promoter activity in all CRH mutant
promoter constructs (Fig. 5).
EtOH treatment did not affect GR mRNA or protein
expression in IVB cells
It is possible that EtOH directly affected GR expression,
thereby altering CRH promoter activity. In order to test this we
measured GR mRNA and protein expression in IVB cells
following treatment with 100 mM EtOH for 0.5 or 2.0 h using
qRT-PCR and Western Blot analysis, respectively. Our data
revealed that there were no changes in GR mRNA expression in
IVB cells relative to baseline (F(4,47)=0.1.889, p=0.128) at any
time point tested (p=0.435 and p=0.082 for 0.5 and 2.0 h,
respectively) or protein levels (Fig. 6A, B).
EtOH treatment precluded GR binding to nGRE on CRH
promoter
We next tested whether GR binding to the nGRE on the CRH
promoter was hindered in the presence of EtOH using chromatin
immunoprecipitation (ChIP) assays. Our results showed a positive
association of GR with the nGRE on the CRH promoter in the
presence of vehicle (media containing 10% FBS) alone, as
expected (Fig. 6C). Treatment with the potent GR agonist,
dexamethasone (DEX) appeared to enhance GR association with
the chromatin, whereas EtOH exposure completely eliminated
GR:chromatin association (Fig. 6C).
Inhibition of protein kinase A (PKA) blocked EtOH-
induced increase in CRH promoter activity
Previous studies have demonstrated that inhibition of PKA
blocked the EtOH-induced increase in CRH [13]. To verify if
PKA is acting similarly in our system, as well as to examine the
potential impact of other kinase pathways, we tested the effects of
EtOH on CRH promoter activity in the presence of three kinase
inhibitors: 1) phosphatidylinositol 3 kinase (PI3K) inhibitor LY
294,190; 2) p38 mitogen activated protein kinase (p38 MAPK)
inhibitor SB 202 190; and 3) the PKA inhibitor H89. As shown in
Fig. 7, the PKA inhibitor H89, but not LY294,190 and SB 202
190, blocked the EtOH-induced increase in CRH promoter
activity at 2.0 h. As expected, EtOH alone significantly increased
CRH promoter activity at 2.0 h (p=0.046). Concomitant
treatment with LY 294,002 (p=0.40 compared to EtOH at 2 h;
Fig. 7A) and SB 202 190 (p=0.42 compared to EtOH at 2 h,
Fig. 7B) had no effect on the EtOH-induced increase in CRH
Figure 3. Effects of 2.0 h EtOH treatment with different doses of EtOH on CRH promoter activity. CRH-luciferase activity was measured in
IVB cell line after treatment with 12.5, 25.0, 50.0 and 100 mM EtOH for 2.0 h or media alone Data expressed as % change in luciferase activity of
vehicle treated control. Dissimilar letters indicate statistically significant difference (P,0.05).
doi:10.1371/journal.pone.0026647.g003
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26647Figure 5. Effects of Forskolin treatment on WT and mutated CRH promoter activity. Luciferase activity was measured in IVB cell line after
treatment with 25 mM Forskolin for 6.0 h (black bars) or vehicle (white bars) in WT CRH promoter or mutated promoter lacking GR binding site 1
(CRHDGR1), GR binding site 2 (CRHDGR2) or GR binding site 1 and 2 (CRHDGR1/2). Data expressed as % change in luciferase activity of vehicle treated
control. Dissimilar letters indicate statistically significant difference (P,0.05).
doi:10.1371/journal.pone.0026647.g005
Figure 4. Effects of EtOH treatment on WT and mutated CRH promoter activity. Luciferase activity was measured in IVB cell line after
treatment with 12.5 mM EtOH for 0.5, 1.0, 2.0 or 4.0 h or vehicle in A) WT CRH promoter, B) promoter lacking GR binding site 1 (CRHDGR1), C) GR
binding site 2 (CRHDGR2) or D) GR binding site 1 and 2 (CRHDGR1/2). Data expressed as % change in luciferase activity from vehicle treated control.
Dissimilar letters indicate statistically significant difference (P,0.05).
doi:10.1371/journal.pone.0026647.g004
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by H89 (p=0.006 compared to EtOH at 2 h, Fig. 7C).
Interestingly, inhibition of p38 MAPK with LY 294,002 alone
significantly increased CRH promoter activity after 2 h, suggesting
that MAPK-mediated phosphorylation events might be important
for maintaining baseline levels of CRH promoter activity.
Together, these data demonstrate that the PKA pathway is
involved in mediating EtOH induced changes in CRH promoter
activity.
100 mM EtOH treatment did not induce cell death
We used a MTT assay to determine whether our highest dose of
EtOH treatment (100 mM) induced cell death in our IVB cell line.
The results showed that EtOH treatment had a significant effect
on cell viability (F(4,10)=3.495, p=0.049, N=3, Fig. 8).
Contrary to what would be expected, EtOH did not decrease
cell viability at any time point measured, rather, it increased
mitochondrial activity at 4.0 h time point.
Discussion
These studies demonstrate for the first time that very low doses
of EtOH (12.5 mM) are sufficient to activate the CRH promoter
and, importantly, have identified a specific nucleotide sequence on
the CRH promoter that is required for EtOH-mediated activity.
Our data showed that EtOH treatment significantly modulates
CRH promoter activity in a time-dependent manner, with a
significant decrease in promoter activity occurring after 0.5 h of
EtOH exposure, followed by a robust (p,0.05) increase after 2 h.
Further, the observed increase in promoter activity at 2 h was
Figure 6. Effects of EtOH treatment on GR mRNA expression,
GR protein levels, and GR:nGRE binding. (A) GR mRNA expression
in IVB cells were measured after treatment with vehicle (white bars) or
100 mM EtOH for 0.5 or 2.0 h (black bars). Data are expressed as fold
change in GR mRNA expression calculated according to the standard
DDct method. (B) GR protein was measured in IVB cells after treatment
with vehicle (lane 1) or 100 mM EtOH for 0.5 (lane 2) or 2.0 h (lane 3)
using Western Blot analysis. Data shown are representative of 3
replicate experiments. (C) IVB cells were treated with vehicle or 100 mM
EtOH for 2 h and processed for chromatin immunoprecipation (ChIP)
assay using GR antibody and primers flanking the nGRE site on the CRH
promoter. PCR products were resolved on a 2% agarose gel. Data
shown are representative of 3 replicate experiments.
doi:10.1371/journal.pone.0026647.g006
Figure 7. Effects of concomitant EtOH and kinase inhibitor
treatments on WT CRH promoter activity. Luciferase activity was
measured in IVB cell line after treatment with 12.5 mM EtOH and 10 mM
(A) LY294,002 (B) SB 202190 (C) H89 for 0.5, 1.0, 2.0 or 4.0 h. Data
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coid receptor signaling, as evidenced by a complete abolishment of
the EtOH-mediated effect using two methods of GR inhibition:
the GR antagonist RU486 and deletion of the GR binding site.
Moreover, we showed that GR binding to the nGRE site on the
CRH promoter was precluded in the presence of EtOH. Taken
together, these data support our hypothesis that alcohol might
increase CRH mRNA expression in the PVN in vivo by directly
interfering with glucocorticoid negative feedback mechanisms
exerted at the level of the CRH promoter.
EtOH has previously been shown to increase intracellular levels
of the second messenger cAMP [19,20]. The CRH promoter
contains one cAMP-responsive site (CRE) located 2224 bp
upstream from the transcription start site. Importantly, the CRE
site lies in close proximity to the nGRE that we targeted in our
studies, and these two sites have been shown to act cooperatively
to modulate normal CRH promoter activity [21]. For instance,
when ligand-bound GRs bind to the nGRE they prevent signaling
of cAMP response element binding protein (CREB) at the CRE
site of the CRH promoter thereby, decreasing the activity of the
promoter and subsequent transcription of CRH mRNA. Based on
our data, we propose that GR-CRH promoter interaction at the
nGRE site is blocked in the presence of EtOH allowing for free
access of phosphorylated CREB to bind the CRE site and thereby,
activate the promoter. Evidence supporting the importance of the
CRE binding site was demonstrated by Li et al., (2005) who
showed that an EtOH-induced increase in CRH promoter activity
was prevented by inhibition of protein kinase A (PKA), a
downstream target of the cAMP signaling pathway [13]. We
replicated these results and also showed that inhibition of the PI3K
and p38 MAPK pathways did not interfere with EtOH’s ability to
increase CRH promoter activity, suggesting that EtOH effects on
CRH are specifically mediated by PKA. Despite differences in cell
lines (hybrid rat neuroblastoma/mouse glioma vs. PVN-derived)
and CRH promoter length (1500 vs. 2100 bp), our results are
consistent with those of Li et al., demonstrating EtOH-induced
increases in CRH promoter activity after 2 h of exposure. Taken
together, these studies provide strong evidence that the CRE and
nGRE sites on the CRH promoter are both important and might
act cooperatively to mediate EtOH action.
Chronic EtOH treatment has been shown to alter GRE:DNA
binding in rat cortex and hippocampus. Adult rats fed a chronic
alcohol diet (Lieber-deCarli, 15 days) had decreased GRE:DNA
binding, as measured by gel electromobility shift assays, that was
fully restored after 72 hours of EtOH withdrawal [22]. Further,
they showed an EtOH-mediated decrease in GR protein levels in
the cortex and hippocampus, which was likely associated with the
observed overall decrease in GR:DNA binding in those same
regions [22]. In our study, we specifically targeted the nGRE
located on the CRH promoter as a potential site for EtOH-
mediated modulation of CRH promoter activity and showed that
GR binding to the nGRE on the CRH promoter was precluded in
the presence of EtOH, although it is important to note that our
results cannot exclude the possibility that EtOH might have also
prevented GR protein:protein interactions with CREB or other
proteins in the larger CREB complex, thereby blocking GR
occupancy at the CRE site as well. Moreover, deletion of portions
Figure 8. Effects of 100 mM EtOH treatment on cell viability in a neuronal cell line. Mitochondrial activity was measured in IVB cell line
after 0.5, 1.0, 2.0 and 4.0 h of 100 mM EtOH treatment. Data expressed as % change of mitochondrial activity relative to vehicle (10% FBS media)
treated controls. Dissimilar letters indicate statistically significant difference (P,0.05).
doi:10.1371/journal.pone.0026647.g008
expressed as % change in luciferase activity from vehicle treated
control. * indicates significant difference compared to control group at
0h( P ,0.05).
doi:10.1371/journal.pone.0026647.g007
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changes in the promoter activity. Deletion of individual sites
(CRHDGR1 or CRHDGR2) abolished the EtOH-induced
increase at 2 h however, a significant increase was observed after
4 h suggesting that EtOH impeded, but did not entirely prevent,
normal GR binding. By contrast, concurrent deletion of both GR
binding sites abolished all EtOH-induced increases in CRH
promoter activity, similar to what was observed in the wild type
CRH promoter following concomitant EtOH treatment with the
GR antagonist, RU486.
Contrary to the results obtained by Roy, et al., we did not
observe any EtOH-mediated changes in GR mRNA or protein
expression [22]. One possibility is that GR protein levels change
with chronic, as opposed to acute, EtOH treatment, although
Spencer and McEwan [23] also noted that there were no changes
in cytosolic fractions of mineralocorticoid receptor (MR) or GR
following chronic EtOH treatment in the brains of adult rats [23].
By contrast, Little at al., (2008) showed that chronic EtOH
treatment (28 week, liquid diet) and 2 week withdrawal increased
nuclear GR protein but did not change the cytosolic GR protein
levels in the prefrontal cortex of male C57BL mice [24]. In our
study we measured GR mRNA and GR protein and did not see
any changes following 2 h of EtOH exposure in a PVN-derived
cell line, suggesting that the discrepancies in the reported literature
might be due to differential effects of EtOH on GR expression in
different brain regions.
The findings herein have furthered our understanding of the
molecular mechanisms of EtOH-induced activation the HPA axis
by demonstrating that the nGRE site is a critical component for
the observed EtOH-mediated increases in CRH promoter activity.
However, we also observed a significant decrease in CRH
promoter activity after 0.5 h of EtOH exposure that was not
explained by cell death or inhibition of GR. The EtOH-induced
decrease in promoter activity following 0.5 h of exposure persisted
in the presence of the GR antagonist RU486, and with all mutant
GR-binding site deletion constructs, suggesting that very short
EtOH exposures do not interfere with normal negative feedback
mechanisms. The mechanism for a rapid EtOH-induced decrease
in CRH promoter activity is still unknown and is being actively
investigated in our ongoing studies.
Overall, results presented in this study show that in a PVN-
derived neuronal cell line, alcohol increased CRH promoter
activity by interfering with GR signaling at the nGRE site of the
promoter, providing a potential molecular mechanism by which
EtOH treatment in vivo increases CRH mRNA levels in the PVN.
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